Monday, 28 September 2026 IPO data updated 2 hours ago
Live GMP
A-One Steels India ₹405 ▲ +₹54 (13.3%) Moneyview ₹34 ▲ +₹14 (41.2%) Roopa Screen ₹64 ▲ +₹32 (50.0%) Bench Mark Infotech Services ₹110 ▲ +₹16 (14.6%) Acevector ₹32 ▲ +₹2 (6.3%) Orient Cables India ₹272 ▲ +₹85 (31.3%) German Green Steel Power ₹139 ▲ +₹27.5 (19.8%) Runwal Enterprises ₹305 ▲ +₹14.5 (4.8%) Dudani Retail ₹29 ▲ +₹3 (10.3%) Shah Investor's Home ₹167 ▲ +₹9 (5.4%) SRIT India ₹130 ▲ +₹32 (24.6%) Robokidz Eduventures ₹106 ▲ +₹80 (75.5%) FX Multitech ₹116 ▲ +₹6 (5.2%) ArMee Infotech ₹375 ▲ +₹8 (2.1%) Adroit Industries India ₹134 ▲ +₹53 (39.6%) Elevate Campuses ₹362 ▲ +₹4 (1.1%) Swastika Infra ₹185 ▲ +₹6 (3.2%) EverestIMS Technologies ₹85 ▲ +₹13 (15.3%) Vans Electroengineerings ₹118 ▲ +₹28 (23.7%) Green Asia Impex ₹90 GMP — Peshwa Wheat ₹101 GMP — Sai Urja Indo ₹113 GMP — Himalayan Solar ₹103 GMP — Shree TNB Polymers ₹52 GMP —

₹1,757 Cr IPO Opens Today: Should You Look at Symbiotec Pharmalab?

₹1,757 Cr IPO Opens Today: Should You Look at Symbiotec Pharmalab?

The Indian IPO market is buzzing again!

🚨 Symbiotec Pharmalab’s ₹1,757 crore IPO opens today, August 24, giving investors another major pharma opportunity.

The IPO has a price band of ₹938–₹988 per share, with a lot size of 15 shares. That means the minimum investment at the upper price band is around ₹14,820.

Key highlights 💊

- IPO Size: ₹1,757 crore

- Price Band: ₹938–₹988

- Lot Size: 15 shares

- IPO Dates: August 24–27

- Fresh Issue: ₹150 crore

- Offer for Sale: ₹1,607 crore

What makes this IPO interesting is Symbiotec’s presence in the pharmaceutical and healthcare space, a sector that continues to attract strong investor interest.

But remember — a popular IPO doesn’t automatically mean a good investment. 📊 Investors should look at the company’s financial performance, valuation, growth prospects and IPO objectives before applying.

The big question: Will Symbiotec Pharmalab deliver strong returns after listing, or is the IPO already priced aggressively? 👀🚨 

This news is for information only and is not investment advice. Please do your own research before making investment decisions.